10x Genomics (TXG) Total Liabilities (2018 - 2026)

10x Genomics has disclosed Total Liabilities across 9 years of filings, most recently posting $201.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $201.4 million, up 2.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $201.4 million (up 2.51% YoY), and the FY2025 annual result was $245.0 million, up 17.52% from the prior year.
• Total Liabilities came in at $201.4 million for Q1 2026 at 10x Genomics, down from $245.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $245.0 million in Q4 2025 to a low of $196.3 million in Q2 2023.
• The 5-year median for Total Liabilities is $208.5 million (2024), against an average of $212.9 million.
• Across the five-year window, Total Liabilities slipped 9.97% in 2023 and advanced 17.52% in 2025, its largest moves.
• 10x Genomics' Total Liabilities stood at $223.2 million in 2022, then increased by 0.39% to $224.1 million in 2023, then dropped by 6.96% to $208.5 million in 2024, then grew by 17.52% to $245.0 million in 2025, then declined by 17.79% to $201.4 million in 2026.
• The last three Total Liabilities figures came in at $201.4 million (Q1 2026), $245.0 million (Q4 2025), and $242.2 million (Q3 2025), per Business Quant data.